TG Therapeutics, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: New York NY United States (1993)

Organization Overview

First Clinical Trial
2012
NCT01647971
First Marketed Drug
2021
umbralisib (Ukoniq)
First NDA Approval
2021
umbralisib (Ukoniq)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TG Therapeutics | TG Therapeutics, Inc. | TG THERAPEUTICS, INC | TG THERAPS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease Progression (Phase 2)

Gastrointestinal Stromal Tumors (Phase 1)

Hodgkin Disease (Phase 1)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Mantle-Cell (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, T-Cell, Peripheral (Phase 1)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 3)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 41
  • # of Trial APIs: 25